Friday, July 10, 2026

pharma · Duchenne muscular dystrophy (DMD) · JAK2V617F-positive high-risk Polycythemia Vera

ITALFARMACO S.P.A

Italfarmaco S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Duchenne muscular dystrophy (DMD), JAK2V617F-positive high-risk Polycythemia Vera, Chronic myeloproliferativ

Cinisello Balsamo, IT HQ
1938 Founded
629 Employees
EMA registrant Type
Company details
Status
Public
HQ
Cinisello Balsamo, IT
Founded
1938
Employees
629
Programs
7
Drugs
17
Patents
0
Clinical program

EFFI2021/01

Approved · small molecule · Female contraception.

EFFI2021/01 for Female contraception. is a Approved program (small_molecule) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).

← All Italfarmaco S.p.A. projects Approved small molecule active

Internal code EFFI2021/01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Italfarmaco S.p.A.
Phase
Approved
Modality
small_molecule
Indication
Female contraception.
Status
active
Trials
1

Clinical trials